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Pathogenic variants in highly penetrant genes are useful for the diagnosis, therapy, and
surveillance for hereditary breast cancer. Large-scale studies are needed to inform future
testing and variant classification processes in Japanese. We performed a case-control
association study for variants in coding regions of 11 hereditary breast cancer genes in 7051
unselected breast cancer patients and 11,241 female controls of Japanese ancestry. Here, we
identify 244 germline pathogenic variants. Pathogenic variants are found in 5.7% of patients,
ranging from 15% in women diagnosed <40 years to 3.2% in patients ≥80 years, with
BRCA1/2, explaining two-thirds of pathogenic variants identified at all ages. BRCA1/2, PALB2,
and TP53 are significant causative genes. Patients with pathogenic variants in BRCA1/2 or
PTEN have significantly younger age at diagnosis. In conclusion, BRCA1/2, PALB2, and TP53
are the major hereditary breast cancer genes, irrespective of age at diagnosis, in Japanese
women.
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Breast cancer is the most common cancer in womenworldwide1. Although several factors such as age, repro-ductive history, and oral contraceptives are known to
contribute to the development of breast cancer, genetic factors
also play an important role2. Pathogenic variants in highly
penetrant hereditary breast cancer genes, such as BRCA1 and
BRCA2 are known to account for 5–10% of breast cancer in the
general population3,4. Association between protein-truncating
variants in 11 different genes and breast cancer risk has been
established3. Although, the precise risk of each gene was uncer-
tain, sequencing of these genes have been recommended to
provide personalized diagnosis, therapy, and surveillance for the
high-risk patients and their relatives5.
Clinical sequencing using multi-gene panel testing has been
widely used for genetic testing of various diseases, including
hereditary breast cancer3. However, this multi-gene panel testing
detects many variants of uncertain clinical significance6. Uncer-
tain classification or misclassification7 of variants can be partially
solved by filtering the variants through the allele frequency
database of various populations, such as the Exome Aggregation
Consortium (ExAC)8. For variants with lower allele frequencies,
additional clinical information including segregation or large-
scale case-control analysis is needed to resolve variant classifica-
tion8. In addition, since almost all the available data are from the
population of the European descendent, it is unclear whether
clinical interpretation are generally applicable to other
populations3.
Here we sequenced 11 established hereditary breast cancer
genes3 in 7051 unselected women with breast cancer and 11,241
controls to estimate the contribution of germline pathogenic
variants in these genes to breast cancer in the Japanese popula-
tion. We also compared the clinical characteristics of breast
cancer patients with versus without a germline pathogenic var-
iant. We identify 244 germline pathogenic variants and we show
demographic and clinical characteristics of patients with patho-
genic variants. We conclude that BRCA1/2, PALB2, and TP53 are
the major hereditary breast cancer genes, irrespective of age at
diagnosis, in Japanese women.
Results
Patient characteristics. Characteristics of female study patients
were shown in Table 1. Mean age at diagnosis of breast cancer
was 55.8 years old. Among them, 0.7% had prior or concurrent
ovarian cancer. Family history of cancer types known to be
associated with hereditary breast cancer syndromes was reported
by breast cancer cases as follows: 11.8% breast, 1.2% ovary, 3.5%
pancreas, 2.9% prostate, and 0.8% thyroid cancer. Characteristics
of male patients were shown in Supplementary Table 1.
Pathogenic germline variants in women. Sequencing of the 11
established hereditary breast cancer genes identified 1781 germ-
line variants among 7051 breast cancer cases and 11,241 controls
(Supplementary Data 1). We annotated clinical significance of
each variant using the association results, known clinical sig-
nificance in ClinVar, population data, computational data, and
functional data following the the American College of Medical
Genetics and Genomics and the Association for Molecular
Pathology (ACMG/AMP) guidelines. After comparing with
ClinVar, we classified 244 variants as pathogenic, 356 as benign
and 1181 as VUS (Supplementary Note 1). Among VUS, two had
conflicting evidence for pathogenic and benign criteria, while the
others did not have enough evidence. Among 244 pathogenic
variants, 204 were disruptive, 38 were non-synonymous, and 2 (p.
Gln1395Gln in BRCA19 and p.Pro3039Pro in BRCA210) were
synonymous but reported to alter splicing, respectively. Among
the 244 pathogenic variants, 131 (53.9%) variants were newly
identified in this study, with the proportion of novel pathogenic
variants ranging from 100% (STK11, 1 unique variant only; NBN,
3 unique variants) to 25% (BRCA1, 55 variants total) (Supple-
mentary Fig. 1). The proportion of pathogenic variants among all
variants differed by gene from 1.3% for STK11 to 33.3% for
PTEN, while the proportion of benign variants ranged from
11.1% for PTEN to 27.0% for CDH1 (Supplementary Table 2).
Supplementary Fig. 2 shows the location of pathogenic
variants. Most variants (75.8%) were singletons and 11.0% were
doubletons. We identified 15 frequent pathogenic variants found
in 5 or more patients in ATM (p.Ile2629fs), BRCA1 (p.Leu63*, p.
Gln934*, p.Lys1095Glu, and p.Tyr1874Cys), BRCA2 (p.Ile605fs,
p.Ile1859fs, p.Ser1882*, p.Asn2135fs, p.Arg2318*, p.Gln3026*,
and p.Pro3039Pro), CHEK2 (p.Ala523Thr), PALB2 (p.Gln559*),
and TP53 (p.Arg248Gln) in Fig. 1. Four variants in BRCA1 (p.
Lys1095Glu and p.Tyr1874Cys), CHEK2 (p.Ala523Thr), and
PALB2 (p.Gln559*) were novel pathogenic variants in this study.
In total, pathogenic variants were found in 404 (5.7%) breast
cancer cases and 67 (0.6%) controls (Fisher’s exact test, P=
2.87 × 10−102, odds ratio (OR)= 10.1). When we performed a
gene-based test using pathogenic variants, four genes were
significantly associated with breast cancer (BRCA2: P= 9.87 ×
10−58, OR= 16.4; BRCA1: P= 3.71 × 10−36, OR= 33.0; PALB2:
P= 5.79 × 10−8, OR= 9.0; and TP53: P= 5.93 × 10−5, OR= 8.5,
Table 2). In addition, PTEN, CHEK2, NF1, and ATM showed
nominal association (P < 0.05). No association was observed for
pathogenic variants in CDH1 (2 cases), NBN (1 case, 3 controls),
and STK11 (1 control). The associated eight genes explained
99.3% of patients with pathogenic variants in this study
(Supplementary Fig. 3A). We also found four breast cancer cases
that had two pathogenic variants (Supplementary Table 3). One
patient had two pathogenic 1-bp deletions (p.Ile917fs and p.
Lys918fs) in BRCA1. Since sequencing analysis showed two
variants cause frame-shift only in one allele, this patient was
considered as a single carrier with a pathogenic variant in BRCA1
for further study. The other three patients had two pathogenic
variants in different genes (a BRCA2 truncating variant plus a
pathogenic variant in ATM or CHEK2), and the number of
double carriers were significantly smaller than expected if we





No. of subjects 7093 11,260
Age at entry (Mean ±
SD)
Years old 59.1 ± 12.0 72.0 ± 7.5
Age at diagnosis
(Mean ± SD)
Years old 55.8 ± 12.0 —
Personal history of
ovarian cancer#




















Yes (%) 54 (0.8) 0 (0.0)
No 7039 11,260
Family history of cancer refers to reported cancer in first and/or second-degree relative
*Controls without past history nor family history of cancers were selected for this study
#Personal history of ovarian cancer includes prior or concurrent ovarian cancer
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hypothesized that pathogenic variants were randomly distributed
to each patient (P= 2.75 × 10−3). Clinical characteristics of the
three double carriers are shown in Supplementary Table 3.
Impact of pathogenic variants on clinical characteristics. To
investigate the impact of pathogenic variants on clinical char-
acteristics of breast cancer, we compared clinical characteristics
between the patients with pathogenic variants and those without
any pathogenic variant (Supplementary Table 4). Breast cancer
patients with pathogenic variants had significantly younger age at
diagnosis, higher frequencies of ovarian cancer, bilateral breast
cancer, advanced clinical stage, triple negative breast cancer and
family history of breast, ovary, pancreas, gastric, liver, bone, and
bladder cancer, respectively.
We further examined the impact of pathogenic variants on the
age at diagnosis of breast cancer by stratifying age at diagnosis
into 10-year age groupings (Fig. 2a). Pathogenic variants were
found in 15.0% of patients diagnosed at less than 40 years old.
The proportion of pathogenic variants significantly decreased
with advancing age at diagnosis (Cochran-Armitage test, P=
1.50 × 10−15). However, we still observed pathogenic variants in
3.2% of breast cancer patients diagnosed at 80 years old or over.
When we examined the age at diagnosis of breast cancer by gene,
we found that the patients with pathogenic variants in PTEN,
BRCA1, and BRCA2 were significantly younger at diagnosis
compared to patients without pathogenic variants (Table 3).
Indeed, 8 of 11 patients with pathogenic variants in PTEN were
diagnosed at <40 years of age and PTEN alterations were the third




















































































Fig. 1 Location and the number of frequent pathogenic variants in six genes in Japanese breast cancer women. Locations of frequent pathogenic variants
found in patients and domains in proteins are shown by lollipop structures, with the variant type indicated by color. Pink, yellow, and green circles indicates
loss of function, non-synonymous, and synonymous variants, respectively. The x-axis reflects the number of amino acid residues, and the y-axis shows the
total number of patients with each pathogenic variant. HGVS.p of frequent variants with five or more patients are shown and four variants newly identified
as pathogenic variants are underlined
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old (Fig. 2b). However, when we divided patients into two groups
by 50 years of age at diagnosis according to the definition of the
National Comprehensive Cancer Network (NCCN) guidelines5,
the proportion of causative genes was not different between the
early-onset and late-onset of breast cancer (χ2-test, P= 0.155,
Supplementary Fig. 3B, C).
Male breast cancer. We conducted the same analysis in 53
unselected male cases and 12,490 controls. We identified 75
pathogenic variants (Supplementary Data 2) in 13 of 53 (24.5%)
male breast cancer patients and 129 of 12,490 (1.0%) male controls
(Fisher’s exact test, P= 1.64 × 10−14, OR= 31.1, Supplementary
Table 5). One patient had two pathogenic variants (p.Thr3033fs in
BRCA2, and p.Val475Met in CDH1). Compared to female breast
cancer patients, the frequency of pathogenic variants in male
breast cancer patients was significantly higher (Fisher’s exact test,
P= 7.93 × 10−6, OR= 5.3). The frequencies of pathogenic var-
iants in male controls were also higher than female controls (1.0%
in male and 0.6% in female, P= 2.31 × 10−4). When we per-
formed a gene-based test, BRCA2 was significantly associated with
male breast cancer (18.9% in cases and 0.2% in controls, Fisher’s
exact test, P= 1.73 × 10−16, OR= 111.2). All pathogenic variants
were found in a single breast cancer patient (Supplementary
Fig. 4). CDH1 and BRCA1 were nominally associated (P < 0.05)
although only one or two patients had a pathogenic variant in
these genes (Supplementary Table 5). When age at diagnosis of
breast cancer was compared between male breast cancer patients
with pathogenic variants in BRCA2 and those with no pathogenic
variant, age at diagnosis of breast cancer was significantly older in
patients with pathogenic variants (mean ± SD, 75.5 ± 5.8 years
old) than those with no pathogenic variant (63.3 ± 10.6 years old,
t-test, P= 3.90 × 10−5).
Discussion
We identified 1781 germline variants in the 11 established her-
editary breast cancer genes in 7051 breast cancer patients and
11,241 controls in women. Although ClinVar has registered many
pathogenic variants of 11 genes, more than half of the 244
pathogenic variants were newly identified in this study. Patho-
genic variants were found in 5.7% of unselected Japanese breast
cancer patients. BRCA1, BRCA2, PALB2, and TP53 were the
significant causative genes. Proportion of pathogenic variants was
high in younger age at diagnosis and gradually decreased with
advancing age at diagnosis. However, we still found the patients
with pathogenic variants diagnosis in elderly women. In addition
to BRCA1/2, we found pathogenic variants in PTEN are asso-
ciated with younger age at onset of breast cancer in Japanese
women.
The 11 genes analyzed in this study have been reported pre-
viously as hereditary breast cancer genes, but the strength of
evidence for association of each gene with breast cancer and
disease risk varies. Further, published risk estimates are likely to
be inflated for at least some genes due to ascertainment bias3. We
observed a significant contribution to breast cancer risk in
BRCA1/2, PALB2, and TP53. The disease risks of BRCA1/2 and
PALB2 are comparable to that previously reported3, but the risk
of TP53 is largely different (8.5 in this study and 105 in the
previous meta-analysis3). This is likely explained by several fac-
tors. Firstly, previous estimates were based on studies of familial
patients presenting with clinical features of Li–Fraumeni syn-
drome, whereas in this study we calculated disease risk for
women unselected for family history of cancer. Second, functional
effects differ between variants in TP53, which causes a wide range
of symptoms, from the severe form known as Li–Fraumeni to the
less severe non-syndromic predisposition11, and it is possible that
the variants found in patients with unselected breast cancer have
less impact on protein function than those identified in patients
with classical Li–Fraumeni syndrome. Among four other genes
showing P < 0.05 (PTEN, CHEK2, NF1, and ATM), the disease
risks of ATM and CHEK2 were comparable to previous reports3.
Disease risks for PTEN and NF1 were not reliably estimated,
despite strong evidence for association (P < 5 × 10−4), due the low
numbers of carriers, indicating need for even larger studies to
estimate risk at the population level. Although the association
with breast cancer for CDH1 and STK11 has been reported pre-
viously for patients for hereditary diffuse gastric cancer12 and
Peutz–Jeghers syndrome13, only two and zero Japanese breast
cancer patients, respectively, had a pathogenic variant in these
genes. That is, CDH1 and STK11 have a limited contribution to
breast cancer in unselected Japanese women. The reported con-
tribution of NBN to breast cancer risk was mainly based on one-
specific variant (c.657del5, rs587776650) in the Slavic
population3,14, which was not observed in the Japanese popula-
tion. Other NBN variants designated as pathogenic using ACMG/
AMP criteria were observed in only 1 case and 3 controls, pro-
viding little support for a role of NBN in Japanese unselected
breast cancer patients. However, our study has confirmed the
importance of the remaining eight genes in genetic testing in
Japan and jointly assessed the disease risk of each gene.
A recent study reported the proportion of pathogenic variants
was 9.3% among 35,409 multi-ethnic women with a single
Table 2 Result of gene-based association test using pathogenic variants
Case (n= 7051) Control (n= 11,241)
Gene No. of pathogenic variants No. of carriers (%) No. of carriers (%) P-value* OR (95% CI)
BRCA2 85 191 (2.71) 19 (0.17) 9.87 × 10−58 16.4 (10.2–28.0)
BRCA1 55 102 (1.45) 5 (0.04) 3.71 × 10−36 33.0 (13.7–103.8)
PALB2 21 28 (0.40) 5 (0.04) 5.79 × 10−8 9.0 (3.4–29.7)
TP53 13 16 (0.23) 3 (0.03) 5.93 × 10−5 8.5 (2.4–45.6)
PTEN 12 11 (0.16) 1 (0.01) 2.16 × 10−4 17.6 (2.6–753.3)
CHEK2 17 26 (0.37) 13 (0.12) 4.31 × 10−4 3.2 (1.6–6.8)
NF1 8 8 (0.11) 0 (0.00) 4.86 × 10−4 Inf (2.7–Inf)
ATM 27 22 (0.31) 17 (0.15) 0.031 2.1 (1.0–4.1)
CDH1 2 2 (0.03) 0 (0.00) 0.149 Inf (0.3–Inf)
NBN 3 1 (0.01) 3 (0.03) 1.000 0.5 (0.0–6.6)
STK11 1 0 (0.00) 1 (0.01) 1.000 0.0 (0.0–62.1)
Sum 244 404# (5.73) 67 (0.60) 2.87 × 10−102 10.1 (7.8–13.4)
*Fisher’s exact test
#Sum of carriers from the 11 genes were 407. However, three patients had two pathogenic variants in different genes. Thus, the number of carriers became 404
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diagnosis of breast cancer who underwent clinical genetic testing
with a 25-gene panel of hereditary cancer genes15. When we
selected 3136 patients meeting NCCN guidelines (Supplementary
Note 2) and compared the proportion of patients with a patho-
genic variant within the 11 genes analyzed in this study, the
proportion of breast cancer patients with pathogenic variants was
similar (Supplementary Table 6), indicating that these clinical
criteria have utility in the Japanese population. However, the
carrier frequencies in BRCA2 and PTEN were significantly higher
in Japanese, while those in ATM and CHEK2 were lower com-
pared to the multi-ethnic study15. One possible explanation might
be the differences in ancestry-specific variants. In our study we
did not identify the CHEK2 1100delC variant, reported in
0.3–3.8% of patients in Europe, North America, and Oceania16,
while three frequent BRCA2 variants (p.Ile605fs, p.Ile1859fs, and
p.Arg2318*) explaining 39.8% of pathogenic BRCA2 variant
carriers in our study were not found in 1824 patients of mostly
European descent17. Therefore, it is important to assess the
contribution of pathogenic variants in hereditary breast cancer
genes using large number of samples in each population.
We identified 113 variants previously noted as pathogenic. The













































































































Relative contribution of genes with a pathogenic variant
Fig. 2 a Proportion of patients with pathogenic variants and b relative contribution of genes by the age at diagnosis of breast cancer women in 10-year-age
groupings. a Proportion of patients with a pathogenic variant significantly decreased with advancing age (Cochran-Armitage test, P= 1.50 × 10−15). b Color
indicates each gene as shown in the right legend






Mean ± SD P-value#
No pathogenic
variants
6240 56.1 ± 11.9 Reference
BRCA2 185 51.0 ± 11.5 9.47 × 10−9†
PTEN 11 36.6 ± 10.5 1.04 × 10−4†
BRCA1 97 50.9 ± 13.0 1.61 × 10−4†
Double carrier 3 48.3 ± 6.7 0.180
TP53 16 50.6 ± 16.3 0.193
PALB2 27 52.9 ± 12.7 0.194
CDH1 2 42.0 ± 7.1 0.217
CHEK2 23 57.9 ± 12.7 0.514
NF1 8 59.5 ± 17.8 0.607
ATM 20 54.7 ± 14.1 0.659
NBN 1 56.0 —
*The number of patients with age at diagnosis is shown
#Mean age at diagnosis of each gene was compared with the patients without pathogenic
variants by t-test
†Significant after the Bonferroni correction was applied
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resulting in a total of 244 pathogenic variants identified. This
increase resulted in the identification of 57% more patients (from
258 to 404) with a pathogenic variant. Supplementary Fig. 5
shows this change in each gene. Although more than 75% of
patients could be identified by only ClinVar in BRCA1/2, only a
small proportion of patients with other genes, especially PALB2
(18%), CHEK2 (8%), ATM (24%), and NF1 (25%), were identi-
fied. Therefore, this study contributes to improved identification
of patients with a pathogenic variant, especially in genes other
than BRCA1/2, in the diagnosis of hereditary breast cancer in
clinical practice in Japan. Next we investigated the proportion of
pathogenic variants shared between other Asian countries and
this study to address how the Japanese data are relevant to other
Asian populations. Two studies from China18 and Malaysia19
sequenced BRCA1/2 in >2000 selected and unselected breast
cancer patients, respectively. The Chinese study identified 175
unique pathogenic variants in 247 of 2991 (8.3%) patients. Of the
175 pathogenic variants, 15 (8.6%) pathogenic variants were
identified in this study. Similarly, the Malaysian study identified
97 unique pathogenic variants in 121 of 2575 (4.7%) patients. Of
these pathogenic variants, 15 (15.5%) variants were identified in
our study. These results suggest that pathogenic variants identi-
fied in this study were shared in Asian populations to some
extent. Therefore, this study contributes to the identification of
patients with a pathogenic variant in the diagnosis of hereditary
breast cancer in other Asian countries. However, it will still be
necessary to create a list of pathogenic variants based on a large
number of samples for improved diagnosis of hereditary breast
cancer.
This study has limitations. First, risk of pathogenic variants
might be overestimated, because we did not use unselected
individuals from the general population as controls. However,
since pathogenic variants were found even in breast cancer
patients diagnosed at elderly, small number of subjects with
pathogenic variants who will develop breast cancer might be
included in the general population. Second, our method could
sequence full coding regions with high quality, but could not
detect large rearrangements and deletions known to cause her-
editary breast cancer. However, the frequency of these rearran-
gements in pathogenic variants is reported to be low for the
BRCA1/2 genes20–22.
In conclusion, because all breast cancer patients in this study
were collected as unselected breast cancer from all over Japan and
a large number of cancer-free controls (Supplementary Note 3, 4)
was jointly analyzed by the same method23, the findings in this
study provide important data to guide genetic testing for breast
cancer susceptibility genes in Asian population.
Methods
Study population. We obtained all study samples from the Biobank Japan24,25,
which is a multi-institutional hospital based registry that collects DNA from per-
ipheral blood leukocytes and clinical information from patients with various
common diseases, including breast cancer, from all over Japan26. In this study, we
analyzed all 7093 female breast cancer patients with DNA available for sequencing.
We also selected 11,260 female controls who were 60 years old or over and do not
have past history nor family history of cancers. Clinical characteristics of cases and
controls were collected by an interview or medical record survey using a standard
questionnaire at the entry to the Biobank Japan. We also examined 53 male breast
cancer patients and 12,520 male controls using the same criteria. We analyzed
women and men separately, as genetic risk for hereditary breast cancer differs
between men and women27 (Supplementary Note 3).
All individuals who participated in this study provided written inform consent.
This study was approved by the ethical committees of the Institute of Medical
Sciences, the University of Tokyo and RIKEN Center for Integrative Medical
Sciences.
Sequencing and bioinformatics analysis. In this study, we analyzed all coding
regions and 2 bp flanking intronic sequences of the 11 established genes causing
hereditary breast cancer3. All transcripts registered in Consensus CDS (CCDS)
release 1528 for each gene were analyzed (Supplementary Table 7). A total length of
the target region was 48,716 bp. A multiplex PCR-based target sequencing method
was used to sequence the target region29. We used a two-step PCR method to
construct DNA libraries. The 1st PCR (25 cycle) was performed with 471 primer
pairs and 2X Platinum Multiplex PCR Master Mix (Thermo Fisher Scientific) to
amplify the target region, followed by the 2nd PCR (4 cycle) with 8-bp barcode and
adapter sequences added using primers targeting shared 5’ overhangs introduced
during the 1st PCR and KAPA HiFi HotStart DNA Polymerase (KAPA). After
purification and quantification of pooled libraries, we sequenced them by 2 × 150-
bp paired-end reads on a HiSeq 2500 (Illumina) instrument. Sequence reads
allocated to each individual were aligned to the human reference sequence (hg19)
using Burrows-Wheeler Aligner (ver. 0.7.12)30 and processed using Genome
Analysis Toolkit (GATK, ver. 3.4-46)31. For quality control, we selected individuals
in which more than 98% of the target region was covered with 20 or more
sequencing reads.
We called variants of each individual separately using UnifiedGenotyper and
HaplotypeCaller of GATK, and VCMM (ver. 1.0.2)32. Genotypes for all individuals
were jointly determined for each variant based on the sequencing read ratio of
reference and alternative alleles. When the alternative allele frequency was between
0 and 0.15, between 0.25 and 0.75, and between 0.85 and 1, we assigned
homozygote of the reference allele, heterozygote, and homozygote of the alternative
allele, respectively. We excluded variants with call rates <98% or variants that did
not follow Hardy–Weinberg equilibrium in controls (P < 1 × 10−6)33. Finally,
99.95% of the target region on average was covered with 20 or more sequence reads
in 7051 female cases, 11,241 female controls, 53 male cases, and 12,490 male
controls.
Annotation of variants. Clinical significance of each variant was annotated
according to the ACMG/AMP guidelines7,34 using association results in this study,
known clinical significance information from ClinVar35, population data from the
1000 genomes project36, ExAC8 and Tohoku Medical Megabank Organization
(ToMMo)37, computational data by in silico programs, and functional data
(Supplementary Note 1). After the annotation, the results were compared with
classifications in ClinVar to identify additional information and determine the final
classification of each variant, collapsed from a 5-tier to 3-tier classification system:
pathogenic, benign, and uncertain significance. The annotation procedure is
detailed in Supplementary Note 1. All these annotations of each variant were
initially performed by YMo, YI, and MK, and reviewed by Japanese experts (T.K.,
T.Y., S.N., K.S., and Y.Mi.). Annotations were further reviewed by M.P. and A.B.S.,
members of the ClinGen-approved BRCA expert panel set up by the Evidence-
based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
consortium38, to assess the consistency of interpretation of the ACMG/AMP
guidelines.
Statistical analysis. Case control association analysis was performed by Fisher’s
exact test under a dominant model. We considered P= 1 × 10−4 as the threshold
for gene-based tests, as recommended previously for breast cancer risk assessment3.
OR and 95% confidence interval (CI) of each variant were also calculated.
To estimate the effect of pathogenic variants on clinical characteristics, we used
t-test for continuous variables and Fisher’s exact test or Cochran-Armitage test for
discrete variables. Proportions of predisposition genes in patients with pathogenic
variants by age at diagnosis were compared by χ2-test. P < 0.05 was considered
statistically significant. Bonferroni correction was applied for multiple
comparisons. All analysis was performed with R statistical package (ver. 3.1.3).
Data availability
Sequence data has been deposited at the Japanese Genotype-phenotype Archive (JGA,
http://trace.ddbj.nig.ac.jp/jga), which is hosted by the DDBJ, under accession number
JGAS00000000140.
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